Findings reported in The American Journal of Pathology suggest specialized proresolving mediators may become therapeutics that alleviate chronic tendon inflammation Source EurekAlert Tendon tears, both to the rotator cuff and Achilles heel, are common injuries, especially in aged individuals. Painful and disabling, they can adversely impact quality of life. New approaches are required to help
Formed 15 years ago, the Genetic Disorders of Mucociliary Clearance Consortium is now co-led by UNC’s Stephanie Davis, MD, to continue advancing knowledge and treatments for genetic chronic pulmonary conditions. Source UNC Health Care To continue the push toward clinical trial readiness for individuals with rare diseases, the National Center for Advancing Translational Sciences, in
Patients with neurological disease that causes blindness, disability go treatment free Source Northwestern University A stem cell transplant reversed a debilitating neurological disease that causes half of the patients to go blind and lose the ability to walk five years after diagnosis. Most of the patients stayed better five years after the transplant and were
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1],[2] Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the retina) as early as week 16 and at one year
Source Wake Forest Baptist Medical Center The Wake Forest Institute for Regenerative Medicine (WFIRM) is the recipient of a major research funding award from the U.S. Department of Health and Human Services (HHS) to support its lung-on-a-chip technology as a model to develop chemical injury treatments. The five-year $24 million program has been approved with an
Source Universitat de Barcelona The League of European Research Universities (LERU) has published a new report on how to improve patients’ access to Advanced Therapy Medicinal Products (ATMPs) in medical centers and university hospitals. In this report, LERU presents recommendations to improve ATMP within the academic context in order to ensure that EU institutions, national
Liver disease patients could one day benefit from a new cell therapy that has just completed its first clinical trial, published in Nature Medicine. Researchers of MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK who tested the potential treatment in patients with liver cirrhosis – where long term damage produces scarring – found
American healthcare is the most expensive in the world, but as much as a quarter of medical spending is being wasted. It’s a figure that amounts to costs of $760 billion to $935 billion per year. That’s according to a study from researchers at Humana, a for-profit American health insurance company. The study, published in JAMA,
Source CancerNetwork CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease, according to study results1 published in Blood Advances. “CAR T cells directed against the B-cell maturation antigen (BCMA) have demonstrated impressive initial results, but available data suggest that most patients with initial responses
